Shots:

• The P-III MOVe-OUT trial evaluates molnupiravir vs PBO in 1550 non-hospitalized adult patients with COVID-19 with at least one risk factor associated with poor disease outcomes & symptom onset within 5 days before randomization
• At the interim analysis- ~50% reduction in the risk of hospitalization or death; patients who received the therapy were either hospitalized or died @29 Day (7.3% vs 14.1%) following randomization- no deaths were reported
• Merck plans to submit an application to the US FDA for EUA imminently based on the P-III results and will submit MAA to other regulatory globally. If authorized- the therapy will be the first oral antiviral medicine for COVID-19

  Ref: Merck | Image: Merck